BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22093788)

  • 1. [An absence of donor TH17 differentiation ameliorates dermal tissue damage].
    Cheng H; Song GL; Pan B; Tian J; Yan ZL; Chen W; Xu KL; Li ZY; Zeng LY
    Zhonghua Yi Xue Za Zhi; 2011 Jul; 91(26):1843-6. PubMed ID: 22093788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of Th17 cells in early onset of mice acute graft versus host disease].
    Cheng H; Zeng LY; Pan B; Song GL; Tian J; Chen C; Yan ZL; Li ZY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):322-5. PubMed ID: 21729601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
    Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Blockage of Th17 cells differentiation exacerbated mouse acute intestine graft-versus-host disease following allogeneic bone marrow transplantation].
    Li HJ; Cheng H; Pan B; Zeng LY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1024-7. PubMed ID: 23363796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of delayed sequential bone marrow transplantation on acute graft-versus-host disease in major H-2 incompatible mouse transplantation].
    Wang CL; Xu KL; Pan XY; Du B
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):92-6. PubMed ID: 18681308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TH17 cells are critical for skin-specific pathological injury in acute graft-versus-host disease.
    Cheng H; Tian J; Li Z; Zeng L; Pan B; Song G; Chen W; Xu K
    Transplant Proc; 2012 Jun; 44(5):1412-8. PubMed ID: 22664026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.
    Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K
    Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental study of Tripterygium hypoglaucum (level) Hutch on preventing acute graft-versus-host disease in bone marrow transplantation mice].
    Li S; Xu KL; Li ZY; Pan XY; Sun HY; Li DP; Cao J; Du B
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):727-30. PubMed ID: 18457261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
    Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ALA-PDT alleviates graft-versus-host disease in mice following allogenic bone marrow transplantation].
    Ran HH; Pan KL; Zhang R; Wang YF
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Oct; 8(5):408-12. PubMed ID: 17052403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
    Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
    Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
    He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.